Literature DB >> 15904482

Isogenic variation of Helicobacter pylori strain resulting in heteroresistant antibacterial phenotypes in a single host in vivo.

Yong Chan Lee1, Sun-Young Lee, Jae Hee Pyo, Dong H Kwon, Jong Chul Rhee, Jae J Kim.   

Abstract

BACKGROUND: Antibiotic-susceptible and -resistant Helicobacter pylori can be present simultaneously in the same host. The aim of this study was to evaluate the genomic diversity of H. pylori strains resulting in heteroresistant antibacterial phenotypes.
MATERIALS AND METHODS: Twenty-one pairs of H. pylori strains isolated from the antrum and body displaying heteroresistant antibacterial phenotypes were included. We compared the genotypes of paired-isolates by random arbitrarily primed polymerase chain reaction (PCR), flagella gene PCR-based restriction fragment length polymorphism, and flaA gene sequencing. In metronidazole-heteroresistant isolates, the sequence variation of rdxA and frxA genes was analyzed using phylogenetic analysis.
RESULTS: The DNA fingerprinting patterns of the paired isolates revealed that 12 pairs (57.1%) were identical, whereas one pair (3.8%) was different. The remaining eight pairs (38.1%) of isolates showed minor heterogenecity in fingerprinting patterns. In flaA gene sequencing, these identical and similar isolates showed close sequence similarity between the antrum and body, whereas different isolate showed 31 points of different nucleotide sequences. Phylogenetic analysis of the metronidazole-heteroresistant pairs showed consistent genetic relatedness of each paired isolates despite the sequence variation of the rdxA or frxA genes in five pairs (71.4%).
CONCLUSIONS: These results suggest that continuing genomic diversities in the same strain may play an important role in modulating the antibiotic-heteroresistant H. pylori in vivo.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15904482     DOI: 10.1111/j.1523-5378.2005.00316.x

Source DB:  PubMed          Journal:  Helicobacter        ISSN: 1083-4389            Impact factor:   5.753


  6 in total

Review 1.  Current progress toward eradicating Helicobacter pylori in East Asian countries: differences in the 2013 revised guidelines between China, Japan, and South Korea.

Authors:  Sun-Young Lee
Journal:  World J Gastroenterol       Date:  2014-02-14       Impact factor: 5.742

2.  Clinical Evaluation of a Real-Time PCR Assay for Simultaneous Detection of Helicobacter pylori and Genotypic Markers of Clarithromycin Resistance Directly from Stool.

Authors:  Rebecca Marrero Rolon; Scott A Cunningham; Jayawant N Mandrekar; Erin T Polo; Robin Patel
Journal:  J Clin Microbiol       Date:  2021-04-20       Impact factor: 5.948

3.  Impacts of H. pylori mixed-infection and heteroresistance on clinical outcomes.

Authors:  Masoud Alebouyeh; Abbas Yadegar; Nastaran Farzi; Marzyieh Miri; Homayoon Zojaji; Somayeh Gharibi; Zeinab Fazeli; Naser Ebrahimi Daryani; Hamid Asadzadeh Aghdaei; Mohammad Reza Zali
Journal:  Gastroenterol Hepatol Bed Bench       Date:  2015

4.  The analysis of virulence factors and antibiotic resistance between Helicobacter pylori strains isolated from gastric antrum and body.

Authors:  Ji Won Seo; Jae Yong Park; Tae-Seop Shin; Jae Gyu Kim
Journal:  BMC Gastroenterol       Date:  2019-08-07       Impact factor: 3.067

Review 5.  Heteroresistance to clarithromycin and metronidazole in patients with a Helicobacter pylori infection: a systematic review and meta-analysis.

Authors:  Ebrahim Kouhsari; Nourkhoda Sadeghifard; Arezoo Khadiv; Hojjat Sayadi; Taghi Amiriani; Sobhan Ghafourian; Hassan Valadbeigi; Marcela Krutova
Journal:  Ann Clin Microbiol Antimicrob       Date:  2022-05-20       Impact factor: 3.944

6.  Clonality Analysis of Helicobacter pylori in Patients Isolated from Several Biopsy Specimens and Gastric Juice in a Japanese Urban Population by Random Amplified Polymorphic DNA Fingerprinting.

Authors:  Nariaki Toita; Shin-Ichi Yokota; Nobuhiro Fujii; Mutsuko Konno
Journal:  Gastroenterol Res Pract       Date:  2013-11-17       Impact factor: 2.260

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.